efavaleukin alfa
Recombinant proteinexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 25, 2021 (NCT04680637)
Timeline
Indications
Mechanism of action
- Interleukin-2Supplementation
IL2 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298204 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05672199 | Phase 2 | Apr 28, 2023 | Amgen |
| NCT04987307 | Phase 2 | Dec 1, 2021 | Amgen |
| NCT04987333 | Phase 1 | Aug 9, 2021 | Amgen |
| NCT04680637 | Phase 2 | May 25, 2021 | Amgen |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 4 | 4 | 2 | 2021 |
1 organizations
Page 1 / 1